N/A N=28 Ankle-foot Orthoses for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=33 Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
N/A N=67 Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
Peripheral Arterial Disease
Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters
N/A N=60 Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)
Popliteal Artery Aneurysm
Primary: Number of Subjects With Primary Patency at 12 Months — 40; 11 Participants
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
N/A N=797 Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
Peripheral Arterial Disease · Quality of Life · Quality of Care
Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants
N/A N=238 Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease
Peripheral Artery Disease · Amputation · Smoking
Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=172 The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
Phase 3 N=159 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Peripheral Arterial Disease
Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
Phase 3 N=366 Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Peripheral Arterial Diseases
Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
Phase 3 N=561 Prostaglandin E1 in Outpatients With Intermittent Claudication
Stage II Peripheral Arterial Occlusive Disease · Intermittent Claudication Fontaine Stage II PAOD
Primary: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline — 2.60; 1.98 meter/meter
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II
Peripheral Arterial Disease
Primary: Clinical Success — 20 Participants
N/A N=1,204 Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
Peripheral Arterial Occlusive Disease
Primary: Procedural Success of Endovascular PAD Treatment(s) — 83.6; 75.8; 68.5 percent of procedures